IRVINE, Calif., and HERSTAL, Belgium, May 6, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today issued its business update for the quarter ended March 31, 2014.
Help employers find you! Check out all the jobs and post your resume.
